Supplement to: Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 phase 3, randomized, double-blind, controlled trial

Name: Supplement to: Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 phase 3, randomized, double-blind, controlled trial
Creator: Athanasios Tsianakas
Published: 2025-11-19T11:21:46.120Z
Keywords: Dermatology, Alopecia Areata

Tsianakas, Athanasios; Passeron, Thierry; Magnolo, Nina; Blume-Peytavi, Ulrike; Kelly, Virginie; Day, Isaiah; Serrao, Rocco; Guttman-Yassky, Emma; Sticherling, Michael; Csernus, Adriana; Moreno-Arrones, Oscar; Hamilton, Colleen; Cassella, James

doi:10.17632/hph8xvmcrb.1

Supplement to: Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 phase 3, randomized, double-blind, controlled trial

Published: 19 November 2025| Version 1 | DOI: 10.17632/hph8xvmcrb.1

Contributors:

Athanasios Tsianakas, Thierry Passeron, Nina Magnolo, Ulrike Blume-Peytavi, Virginie Kelly, Isaiah Day, Rocco Serrao, Emma Guttman-Yassky, Michael Sticherling, Adriana Csernus, Oscar Moreno-Arrones, Colleen Hamilton, James Cassella

Description

Supplementary appendix to the manuscript titled "Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 phase 3, randomized, double-blind, controlled trial" by Athanasios Tsianakas, Thierry Passeron, Nina Magnolo, Ulrike Blume-Peytavi, Virginie Kelly, Isaiah Day, Rocco Serrao, Emma Guttman-Yassky, Michael Sticherling, Adriána Evelin Csernus, Oscar M. Moreno-Arrones, Colleen Hamilton, James Cassella in the Journal of the American Academy of Dermatology.

Supplement to: Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 phase 3, randomized, double-blind, controlled trial

Description

Files

Categories

Licence